Bong-soo S. Cha

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 123 publications

Lower glucagon response and attenuated hepatic glucagon signaling in MASLD.

Lower glucagon response and attenuated hepatic glucagon signaling in MASLD.

Journal: Diabetes & metabolism

Published: June 17, 2026

Intermittent Fasting and Risk of Diabetic Retinopathy: Retrospective Data from the National Health and Nutrition Examination Survey.

Intermittent Fasting and Risk of Diabetic Retinopathy: Retrospective Data from the National Health and Nutrition Examination Survey.

Journal: Nutrients

Published: May 04, 2026

Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real-World Observational Study.

Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real-World Observational Study.

Journal: Diabetes, obesity & metabolism

Published: January 15, 2026

Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trial.

Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trial.

Journal: Diabetes, obesity & metabolism

Published: December 16, 2025

Efficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study.

Efficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study.

Journal: Diabetes & metabolism journal

Published: November 13, 2025

Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes.

Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes.

Journal: Diabetes & metabolism journal

Published: October 01, 2025

Protective Role of Serum β-Hydroxybutyrate in Early Diabetic Kidney Disease: A Longitudinal Study.

Protective Role of Serum β-Hydroxybutyrate in Early Diabetic Kidney Disease: A Longitudinal Study.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders

Published: September 01, 2025

Lobeglitazone improves glycaemic control as add-on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double-blind, randomised, placebo-controlled trial.

Lobeglitazone improves glycaemic control as add-on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double-blind, randomised, placebo-controlled trial.

Journal: Diabetes, obesity & metabolism

Published: July 05, 2025

Metabolic Dysfunction-Associated Steatotic Liver Disease and Low Handgrip Strength Are Associated with a Higher Risk of Cardiovascular Disease.

Metabolic Dysfunction-Associated Steatotic Liver Disease and Low Handgrip Strength Are Associated with a Higher Risk of Cardiovascular Disease.

Journal: Journal of obesity & metabolic syndrome

Published: June 20, 2025

Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study.

Efficacy and safety of pioglitazone versus dapagliflozin as an add-on to metformin and alogliptin combination therapy: the EPIDOTE study.

Journal: Scientific reports

Published: June 05, 2025

2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association.

2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association.

Journal: Diabetes & metabolism journal

Published: May 28, 2025

Impact of initial severity and progression pattern of new-onset diabetes on pancreatic cancer risk: a 15-year longitudinal nationwide cohort study.

Impact of initial severity and progression pattern of new-onset diabetes on pancreatic cancer risk: a 15-year longitudinal nationwide cohort study.

Journal: Gut

Published: May 13, 2025

Showing 1-12 of 123

Last Updated: 09/26/2026